ISSN: 2332-0877

Журнал инфекционных заболеваний и терапии

Открытый доступ

Наша группа организует более 3000 глобальных конференций Ежегодные мероприятия в США, Европе и США. Азия при поддержке еще 1000 научных обществ и публикует более 700 Открытого доступа Журналы, в которых представлены более 50 000 выдающихся деятелей, авторитетных учёных, входящих в редколлегии.

 

Журналы открытого доступа набирают больше читателей и цитируемости
700 журналов и 15 000 000 читателей Каждый журнал получает более 25 000 читателей

Абстрактный

A Proposed Protocol for the Investigation of the Safety and Efficacy of the COVID-19 Vaccine for Patients with Psychosis and Pilot Safety Findings from a Chinese Psychiatrist?s Self-Experiment

Yun Sun, Chongguang Lin, Jiayue Chen, Qianchen L, Weiliang Yang, Cong Yao, Lina Wang, Ziyao Cai, Jing Ping, Ce Chen,Langlang Cheng, Jinjing Zhu, Guangdong Chen, Peiwei Shan, Chunmian Chen, Tao Fang, Hongjun Tian and Chuanjun Zhuo

We present a study protocol designed to test the safety and efficacy of the 2019 Coronavirus Disease (COVID-19) vaccine in
patients with major psychotic disease. A secondary objective is to investigate optional vaccination methods for these patients. In a selfexperiment,
a Chinese psychiatrist examined the safety and efficacy of the COVID-19 vaccine under clinical use of typical antipsychotic
agents and sedatives (olanzapine, duloxetine, and diazepam). For patients with extremely drug-resistant conditions, the safety of the
COVID-19 vaccine under electroconvulsive therapy was also investigated. The entire study process was recorded on high-definition
video. This clinical study protocol is, to our knowledge, the first of its kind. Our findings will shed new light on the protection of patients
with psychotic diseases from COVID-19 infection.